Theravance Biopharma Inc (TBPH)

Jul 25, 2025

Theravance Biopharma Inc. Stock Analysis and ForecastOutstanding capital appreciation - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

Is Theravance Biopharma Inc. a good long term investmentFree Predictions - Autocar Professional

Jul 25, 2025

Jul 25, 2025

Why Theravance Biopharma Inc. stock attracts strong analyst attentionWealth Accumulation Stock List - Newser

Jul 25, 2025

Jul 24, 2025

What analysts say about Theravance Biopharma Inc. stockUnbelievable profit margins - PrintWeekIndia

Jul 24, 2025

Jul 23, 2025

Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune

Jul 23, 2025

Jul 22, 2025

What drives Theravance Biopharma Inc. stock priceConsistent triple-digit returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

How Theravance Biopharma Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser

Jul 22, 2025

Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025

Jul 16, 2025

Theravance Biopharma SVP Farnum sells $113,869 in stock By Investing.com - Investing.com Nigeria

Jul 16, 2025

Jul 16, 2025

Theravance Biopharma SVP Farnum sells $113,869 in stock - Investing.com

Jul 16, 2025

Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025

Jul 15, 2025

What makes Theravance Biopharma Inc. stock price move sharplyStrategic High Profit Opportunities - Newser

Jul 15, 2025

Jul 15, 2025

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey

Jul 15, 2025

Jul 15, 2025

Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60 - Defense World

Jul 15, 2025

Jul 14, 2025

Theravance Biopharma SVP Sells 7,000 Shares for $78,000 on July 14, 2025. - AInvest

Jul 14, 2025

Jul 13, 2025

Theravance higher as China approves Viatris-partnered COPD therapy - MSN

Jul 13, 2025

Jul 12, 2025

Theravance Biopharma (NASDAQ:TBPH) Downgraded to “Hold” Rating by Wall Street Zen - Defense World

Jul 12, 2025

Jun 30, 2025

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Theravance Biopharma, Inc.(NasdaqGM: TBPH) added to Russell Microcap Growth Index - MarketScreener

Jun 30, 2025

Jun 28, 2025

Theravance Biopharma (NASDAQ:TBPH) Given New $25.00 Price Target at BTIG Research - Defense World

Jun 28, 2025

Jun 27, 2025

TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News - GuruFocus

Jun 27, 2025